A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of (LCAR)-G08, a Chimeric Antigen Receptor (CAR)-T Cell Therapy Targeting Guanylyl Cyclase C (GCC) in Subjects With Advanced Gastrointestinal Tumors
Latest Information Update: 03 Jan 2025
At a glance
- Drugs LCAR G08 (Primary)
- Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 15 Jan 2024 New trial record